Mediterranean Diet, Exercise and Dementia Risk in UK Adults

In MedEx-UK the investigators propose to conduct a feasibility study in three UK centres (Norwich, Birmingham, Newcastle) which collectively will recruit 108 UK older adults (55-74y) who are at above average risk of dementia, but pre-clinical. Primary outcome is to evaluate the feasibility of a multi-domain intervention to increase MDP adherence and PA over a 24 week period, and to demonstrate the possibility of achieving meaningful behavioural change in a UK population. Secondary outcomes will be to measure the sensitivity of various cognitive assessments and measure the variability of our primary and secondary outcome measures in this population at baseline and in response to intervention.

There are three intervention arms to the study, and participants will be randomised with minimisation for gender and Mediterranean Diet Adherence Screener score (MEDAS; a validated questionnaire)

• MDP:

Participants will be asked to alter their consumption of foods consistent with a Mediterranean Diet. Examples include increased intake of fruits and vegetables, nuts, olive oil as the main culinary fat, moderate wine consumption (if they already consume alcohol), preferring white meat over red, and a reduction in commercial sweet and pastries, and sugar-sweetened drinks.

• MDP plus PA:

As well as the dietary intervention as in 1., participants will be asked to increase their PA using a mixture of structured (e.g. dancing, Zumba classes, swimming etc.) and non-structured (walking up stairs, gardening etc.) activities.

• Control:

Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and UK British Heart Foundation (BHF) guidelines.

The overall purpose of this study is to inform the feasibility and design of a future large-scale UK dementia risk reduction RCT, to observe whether a multi-domain intervention over 2 to 5 years promoting MDP adherence and increased PA can reduce cognitive decline and brain atrophy in adults at above average risk of dementia.

Inclusion criteria

• Male and female, aged 55-74 years
• Understands and is willing and able to comply with all study procedures, including changes to diet and physical activity levels
• Access to, and able to use, the internet/computer/tablet device
• QRISK3 score of >=15 (assessed by GP)
• Subjective Memory Complaints (SMC), based on a score of >16 on the Cognitive Change Index (CCI) (from the first 12 items)
• Stable use of any prescribed medication for at least four weeks
• Normal (or corrected to normal) vision and hearing
• Fluent in written and spoken English
• Willing and able to provide written informed consent

Exclusion criteria

• Diagnosis of Alzheimer's disease (AD), other form of dementia, Mild Cognitive Impairment (MCI), or significant neurological disorder
• Cognition not within normal range, based on a score of <26 on the Montreal Cognitive Assessment (MoCA); or an indication of cognitive decline, based on a score of ≥2 on Ascertain Dementia (AD-8)
• Evidence of impairment of Instrumental Activities of Daily living (IADLS)
• Moderate to severe depression, assessed by the Patient Health Questionnaire (PHQ-9), a score of >10 being exclusionary
• Moderate to severe anxiety, assessed by the Generalised Anxiety Disorder Assessment (GAD-7), a score of >10 being exclusionary
• Current psychotic illness (delusional disorder/schizophrenia)
• History of serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder)
• Subjects with other clinically diagnosed psychiatric disorders likely to affect the cognitive measures (as judged by a clinical advisor)
• HIV positive
• Past history or previous MRI evidence of brain damage, significant head trauma (including loss of consciousness as a result), brain surgery, stroke, or serious neurological disorders
• History of alcohol or drug dependency in the last 2 years
• Subjects with existing diagnosed gastrointestinal disorders likely to impact study results (as judged by a clinical advisor)
• History of any major cardiovascular event, such as a myocardial infarction, stroke or TIA
• Diagnosed COPD
• Cancer, or cancer/treatment within the last 12 months
• Diagnosis of type 1 or type 2 diabetes < 3 months ago
• Clinical diagnosis of liver or kidney disease
• Diagnosed Epilepsy
• Subjects with any other existing medical conditions likely to affect the study measures
• BMI >40kg/m2
• A habitual Mediterranean Diet Score (MDS) ≥9
• Habitual physical activity of >60 minutes moderate activity per week, assessed using the International Physical Activity Questionnaire (IPAQ), short form
• Currently actively engaged in a weight loss, other dietary, or physical activity intervention
• Prescribed medications likely to influence the study measures (as judged by a clinical advisor)
• Currently a participant or have participated in any other study involving an investigational product in the last 4 weeks
• Metal implants, e.g. pacemaker that precludes MRI.
• Claustrophobic which precludes MRI scanning.